Dr. von Minckwitz on the Safety Profile of the APHINITY Trial for HER2+ Breast Cancer

Gunter von Minckwitz, MD, PhD
Published: Thursday, Jul 06, 2017



Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses the safety profile of the phase III APHINITY trial for patients with HER2-positive breast cancer.

There has been a safety analysis of the APHINITY trial that focused on the impact on the cardiac toxicity, which was shown to be very low, explains von Minckwitz.

The most significant grade 3 side effect that was experienced was diarrhea, states von Minckwitz. This was confined to the chemotherapy period of the trial.

SELECTED
LANGUAGE


Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses the safety profile of the phase III APHINITY trial for patients with HER2-positive breast cancer.

There has been a safety analysis of the APHINITY trial that focused on the impact on the cardiac toxicity, which was shown to be very low, explains von Minckwitz.

The most significant grade 3 side effect that was experienced was diarrhea, states von Minckwitz. This was confined to the chemotherapy period of the trial.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x